Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 5/20 | 0.83 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977449 | 1.00 | PREP (0.83) | PREPACE2NPSR1ALDH1A1CTRB1 | |
| SCHEMBL7268391 | 0.91 | PREP (1.00) | PREPNPSR1ALDH1A1CTRB1TSHR | |
| SCHEMBL7269041 | 0.91 | PREP (1.00) | PREPNPSR1ALDH1A1CTRB1TSHR | |
| SCHEMBL16419544 | 0.89 | PREP (0.67) | PREPACE2NPSR1ALDH1A1CTRB1 | |
| SCHEMBL13532966 | 0.87 | PREP (0.65) | PREPACE2NPSR1CTRB1TSHR | |
| SCHEMBL8272821 | 0.87 | PREP (0.65) | PREPACE2NPSR1CTRB1TSHR | |
| SCHEMBL9873735 | 0.86 | PREP (0.64) | PREPACE2NPSR1CTRB1TSHR | |
| Hydrochloric Acid SCHEMBL2437118 | 0.86 | PREP (0.64) | PREPACE2NPSR1CTRB1TSHR | |
| SCHEMBL7836712 | 0.86 | PREP (0.64) | PREPACE2NPSR1CTRB1TSHR | |
| SCHEMBL19258607 | 0.86 | PREP (0.63) | PREPACE2NPSR1CTRB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198722-A1 | Collections of compounds | SPIROGEN LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6747144-B1 | TREATING NEOPLASTIC DISEASES, ALZHEIMER'S DISEASE, BACTERIAL INFECTIONS, PARASITIC INFECTIONS OR VIRAL INFECTIONS | SPIROGEN LIMITED (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1107970-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012509-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198722-A1 | Collections of compounds | CBR3, H1-3, H1-0 | PREP 4168/4885ACE2 2444/4885NPSR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.